Table 3.

Association between adipokines and the metabolic syndrome, stratified to quartiles of visceral adipose tissue.

Adipokine	Q1 (3.4–7.5 cm) OR (95% CI)	Q2 (7.6–9.2 cm) OR (95% CI)	Q3 (9.3–11.1 cm) OR (95% CI)	Q4 (11.2–18.9 cm) OR (95% CI)	P for interaction
MCP-1	0.76 (0.53–1.08)	0.97 (0.68–1.37)	1.03 (0.74–1.44)	0.84 (0.62–1.14)	0.49
NGF	0.81 (0.54–1.21)	1.15 (0.79–1.67)	1.25 (0.90–1.72)	0.94 (0.70–1.28)	0.36
HGF	0.94 (0.65–1.35)	0.92 (0.62–1.37)	1.05 (0.78–1.40)	0.93 (0.66–1.32)	0.84
PAI-1	0.96 (0.57–1.61)	1.39 (0.93–2.06)	0.93 (0.68–1.28)	0.78 (0.59–1.03)	0.94
MIF	1.18 (0.75–1.85)	1.07 (0.71–1.62)	1.09 (0.80–1.47)	1.09 (0.77–1.54)	0.70
Adipsin	0.99 (0.65–1.50)	1.04 (0.71–1.52)	0.85 (0.63–1.15)	0.84 (0.63–1.12)	0.15
Adiponectin	0.58 (0.35–0.97)	0.68 (0.45–1.03)	0.64 (0.45–0.91)	0.76 (0.57–1.01)	0.51
Resistin	0.62 (0.38–1.00)	0.95 (0.64–1.40)	0.84 (0.63–1.12)	0.88 (0.68–1.16)	0.21
Chemerin	0.91 (0.59–1.41)	1.02 (0.70–1.49)	0.83 (0.59–1.15)	0.86 (0.64–1.16)	0.18
SAA1	0.84 (0.56–1.27)	1.27 (0.83–1.93)	1.01 (0.72–1.40)	0.79 (0.60–1.05)	0.40
Leptin	0.88 (0.56–1.40)	1.43 (0.97–2.11)	1.00 (0.70–1.43)	0.90 (0.66–1.23)	0.71

Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs) for the presence of the metabolic syndrome with a 1 SD increase in adipokines, stratified into quartiles of visceral adipose tissue (VAT, in cm).

P value for interaction is the interaction of continuous measured VAT in the relation between adipokines and the metabolic syndrome.

MCP-1: monocyte chemoattractant protein 1; NGF: nerve growth factor; HGF: hepatic growth factor; PAI-1: plasminogen activator inhibitor 1; MIF: migration inhibitory factor; SAA1: serum amyloid A.